当前位置: X-MOL 学术Adv. Drug Deliver. Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration
Advanced Drug Delivery Reviews ( IF 16.1 ) Pub Date : 2018-01-08 , DOI: 10.1016/j.addr.2018.01.003
William L. Hwang , Haley M. Pleskow , David T. Miyamoto

Advances in our molecular understanding of cancer biology have paved the way to an expanding compendium of molecularly-targeted therapies, accompanied by the urgent need for biomarkers that enable the precise selection of the most appropriate therapies for individual cancer patients. Circulating biomarkers such as circulating tumor cells (CTCs) are poised to fill this need, since they are “liquid biopsies” that can be performed non-invasively and serially, and may capture the spectrum of spatial and temporal tumor heterogeneity better than conventional tissue biopsies. Increasing evidence suggests that moving beyond the enumeration of CTCs towards more sophisticated molecular analyses can provide actionable data that may predict and potentially improve clinical outcomes. In this review, we discuss the potential of molecular CTC analyses to serve as prognostic and predictive biomarkers to guide cancer therapy and early cancer detection. As technologies to capture and analyze CTCs continue to increase in sophistication, we anticipate that the potential clinical applications of CTCs will grow exponentially in the coming years.



中文翻译:

循环肿瘤细胞的分子分析:无法枚举的生物标志物

我们对癌症生物学的分子理解的进步为分子靶向疗法的广泛应用铺平了道路,同时迫切需要能够为个体癌症患者精确选择最合适疗法的生物标志物。循环生物标记物(例如循环肿瘤细胞(CTC))可以满足这种需求,因为它们是“液体活检”,可以非侵入性和连续方式进行,并且比常规组织活检可以更好地捕获时空异质性频谱。越来越多的证据表明,从四氯化碳的列举转向更复杂的分子分析可以提供可行的数据,这些数据可以预测并可能改善临床结果。在这篇评论中,我们讨论分子CTC分析作为指导癌症治疗和早期癌症检测的预后和预测生物标志物的潜力。随着捕获和分析CTC的技术不断发展,我们预计CTC的潜在临床应用在未来几年将成倍增长。

更新日期:2018-01-08
down
wechat
bug